Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Apr 14, 2014; 20(14): 3938-3949
Published online Apr 14, 2014. doi: 10.3748/wjg.v20.i14.3938
Endoscopic submucosal dissection for undifferentiated-type early gastric cancer: Do we have enough data to support this?
Choong Nam Shim, Sang Kil Lee
Choong Nam Shim, Sang Kil Lee, Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul 120-752, South Korea
Author contributions: Shim CN contributed to study concept and design, data collection, analysis, and drafting of the manuscript; Lee SK contributed to study concept and design, critical revision of the manuscript, and study supervision.
Correspondence to: Sang Kil Lee, MD, PhD, Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, South Korea. sklee@yuhs.ac
Telephone: +82-2-2228996 Fax: +82-2-3936884
Received: October 27, 2013
Revised: January 18, 2014
Accepted: February 17, 2014
Published online: April 14, 2014
Processing time: 168 Days and 12.4 Hours
Core Tip

Core tip: Endoscopic submucosal dissection (ESD) for intramucosal undifferentiated (UD) type early gastric cancer (EGC) without ulceration and with diameter ≤ 2 cm is regarded as an investigational treatment according to the Japanese gastric cancer treatment guidelines. In contrast, the controversial results about the safety of ESD for UD-EGC fulfilling the criteria have been reported and a little is known about the long-term outcomes. Therefore, in this review, we focused on the safety and therapeutic efficacy of ESD for UD-EGC with reference to risks for lymph node metastasis within the proposed criteria as well as the short-term and long-term outcomes of ESD for UD-EGC.